The addition of three more conditions to Connecticut’s medical marijuana program cleared another hurdle Friday.
Consumer Protection Commissioner Michelle H. Seagull announced in a statement Friday that she would follow the Medical Marijuana Program Board of Physicians’ recommendation to add the three conditions: hydrocephalus with intractable headaches, intractable migraines, and trigeminal neuralgia.
Seagull told The Courant Thursday that she would likely follow the recommendations, but Friday’s announcement ensures the additions will move to the next round of approval.
“After DCP drafts a regulation to add the conditions, there will be an additional public hearing and comment period,” Seagull said in the statement.
That step should be completed soon: Seagull said Thursday she expects the draft of the regulations to be completed by the end of the month. The public comment period will then last 30 days.
After that, the process slows down as it endures the same review process as all other state regulations.
The regulation then will be reviewed by the office of the attorney general, and ultimately will require the approval of the Regulation Review Committee of the General Assembly, Seagull said. That could take as long as a year, she said.
The three conditions approved by Seagull Friday join four others that were approved in February: fibromyalgia, rheumatoid arthritis, shingles and muscular dystrophy. There are currently 22 conditions for which adults in Connecticut may receive medical marijuana, and six conditions for children under 18.
